From the Department of Cardiology, Tel Aviv Medical Center, Tel Aviv; affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel.
From the Department of Cardiology, Tel Aviv Medical Center, Tel Aviv; affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel.
Am J Cardiol. 2021 May 1;146:62-68. doi: 10.1016/j.amjcard.2021.01.022. Epub 2021 Feb 1.
Current risk models have only limited accuracy in predicting transcatheter aortic valve Implantation (TAVI) outcomes and there is a paucity of clinical variables to guide patient management after the procedure. The prognostic impact of elevated left ventricular end-diastolic pressure (LVEDP) in TAVI patients is unknown. The aim of the present study was to evaluate the prognostic value of after-procedural LVEDP in patients who undewent TAVI. Consecutive patients with severe symptomatic aortic stenosis who undewent TAVI were divided into 2 groups according to after-procedural LVEDP above and below or equal 12 mm Hg. Collected data included baseline clinical, laboratory and echocardiographic variables. We evaluated the impact of elevated vs. normal LVEDP on in-hospital outcomes, short- and long-term mortality. Eight hundred forty-five patients were included in the study with complete in-hospital and late mortality data available for all survivors (median follow-up 29.5 months [IQR 16.5 to 48.0]). The mean age (±SD) was 82.3±6.2 years and mean Society of Thoracic Surgery score was 4.0%±3.0%. Patients with LVEDP>12 mm Hg (n = 591, 70%) and LVEDP≤12 mm Hg (n = 254, 30%) had a 6-months mortality rate of 6.8% and 2%, respectively (P=0.004) and a 1-year mortality rate of 10.1% vs 4.9%, respectively (p = 0.017). By multivariable analysis, after-procedural LVEDP>12 mm Hg was independently associated with all-cause mortality (HR 2.45, 95% CI 1.58 to 3.76, p <0.001) during long-term follow-up. In conclusion, elevated after-procedural LVEDP in patients who undewent TAVI is an independent predictor of mortality following TAVI. Further research regarding the use of LVEDP as a tool for after-procedural medical management is warranted.
目前的风险模型在预测经导管主动脉瓣植入术(TAVI)结果方面准确性有限,并且缺乏指导术后患者管理的临床变量。TAVI 患者左心室舒张末期压(LVEDP)升高的预后影响尚不清楚。本研究旨在评估 TAVI 患者术后 LVEDP 升高的预后价值。
连续接受 TAVI 的严重症状性主动脉瓣狭窄患者根据术后 LVEDP 高于或等于 12mmHg 和低于 12mmHg 分为两组。收集的数据包括基线临床、实验室和超声心动图变量。我们评估了升高的 LVEDP 与正常 LVEDP 对住院期间结局、短期和长期死亡率的影响。
845 例患者纳入研究,所有幸存者均有完整的住院和晚期死亡率数据(中位随访 29.5 个月[IQR 16.5 至 48.0])。患者的平均年龄(±SD)为 82.3±6.2 岁,平均胸外科协会评分(STS)为 4.0%±3.0%。LVEDP>12mmHg(n=591,70%)和 LVEDP≤12mmHg(n=254,30%)患者的 6 个月死亡率分别为 6.8%和 2%(P=0.004),1 年死亡率分别为 10.1%和 4.9%(P=0.017)。多变量分析显示,术后 LVEDP>12mmHg 与全因死亡率独立相关(HR 2.45,95%CI 1.58 至 3.76,P<0.001)。
总之,TAVI 后 LVEDP 升高是 TAVI 后死亡率的独立预测因素。需要进一步研究 LVEDP 作为术后药物治疗工具的使用。